The Experts below are selected from a list of 108 Experts worldwide ranked by ideXlab platform
Robert R. Wolfe - One of the best experts on this subject based on the ideXlab platform.
-
106 Local Injection of Insulin‐Zinc Suspension Stimulates DNA Synthesis in Skin Donor Wound
Wound Repair and Regeneration, 2008Co-Authors: Xiao-jun Zhang, David L. Chinkes, Robert R. WolfeAbstract:We have previously reported that local injection of small doses of long-acting Insulin-Zinc Suspension maintained sufficiently high Insulin concentration in the wound fluid and accelerated the healing. The present experiment was to measure the rates of cell proliferation (reflected by DNA synthesis) and protein metabolism in the wound. These are the underlying metabolic processes responsible for the healing. Partial thickness skin donor wound was created on the back and indwelling catheters were placed in the carotid artery and jugular vein in adult rabbits under general anesthesia. The wound was covered with Aquaphor gauze, OpSite membrane, and surgical gauze. On day 7 after wounding, the wound was either injected with 0.2 units of Insulin-Zn, Zn alone, or no injection; stable isotopes were infused into the jugular vein catheter in conscious rabbits for measurement of DNA synthesis, protein synthesis and breakdown in the wound. The local Insulin-Zn injection raised wound Insulin concentration to 168 ± 39 μU/ml. In contrast, in the control and Zn groups wound Insulin concentrations were below the detectable level. The local injection of Insulin-Zn Suspension increased (p = 0.03) DNA synthesis in the wound with minor changes in blood glucose concentration which did not require exogenous glucose replacement. In the Zn group, whereas the rate of DNA synthesis tended to increase (p = 0.051 vs. control), the protein net balance (synthesis – breakdown) was lower (p
-
106 local injection of Insulin Zinc Suspension stimulates dna synthesis in skin donor wound
Wound Repair and Regeneration, 2008Co-Authors: Xiao-jun Zhang, David L. Chinkes, Robert R. WolfeAbstract:We have previously reported that local injection of small doses of long-acting Insulin-Zinc Suspension maintained sufficiently high Insulin concentration in the wound fluid and accelerated the healing. The present experiment was to measure the rates of cell proliferation (reflected by DNA synthesis) and protein metabolism in the wound. These are the underlying metabolic processes responsible for the healing. Partial thickness skin donor wound was created on the back and indwelling catheters were placed in the carotid artery and jugular vein in adult rabbits under general anesthesia. The wound was covered with Aquaphor gauze, OpSite membrane, and surgical gauze. On day 7 after wounding, the wound was either injected with 0.2 units of Insulin-Zn, Zn alone, or no injection; stable isotopes were infused into the jugular vein catheter in conscious rabbits for measurement of DNA synthesis, protein synthesis and breakdown in the wound. The local Insulin-Zn injection raised wound Insulin concentration to 168 ± 39 μU/ml. In contrast, in the control and Zn groups wound Insulin concentrations were below the detectable level. The local injection of Insulin-Zn Suspension increased (p = 0.03) DNA synthesis in the wound with minor changes in blood glucose concentration which did not require exogenous glucose replacement. In the Zn group, whereas the rate of DNA synthesis tended to increase (p = 0.051 vs. control), the protein net balance (synthesis – breakdown) was lower (p < 0.05) than those in the control and Insulin-Zn (Table 1). We conclude that local injection of a small dose (0.2 units Insulin) long-acting Insulin-Zn Suspension stimulated wound DNA synthesis without major systemic side effects thereby providing an effective and safe approach to accelerate wound healing. Although local Zn injection might also stimulate wound DNA synthesis, the benefit on the healing process was limited by decreased net protein deposition. Table 1. Wound DNA and protein metabolism. DNA synthesis Protein synthesis Protein net balance Values are means ± SD in %/d. * p < 0.05 vs. control; + p = 0.051 vs. control;#, p < 0.05 vs. control and Insulin-Zn by one-way ANOVA. Control (n = 7) 2.9 ± 0.9 20.5 ± 8.4 7.9 ± 6.0 Insulin-Zn (n = 7) 4.2 ± 0.9* 17.9 ± 8.2 9.4 ± 6.4 Zn (n = 7) 4.1 ± 0.9+ 13.0 ± 5.8 −0.2 ± 3.4#
-
Local Insulin-Zinc injection accelerates skin donor site wound healing.
Journal of Surgical Research, 2007Co-Authors: Xiao-jun Zhang, David L. Chinkes, Steven E. Wolf, Hal K. Hawkins, Robert R. WolfeAbstract:Background Systemically administered Insulin has been shown to accelerate wound healing. To minimize the hypoglycemic and hypokalemic effects of Insulin, we investigated a new route of Insulin administration by local injection into skin wounds. Materials and methods Partial thickness skin donor site wounds were created on the backs of adult rabbits with a dermatome set at 0.015 inch. The wounds were covered by Aquaphor gauze (Smith and Nephew, Largo, FL), and OpSite membrane (Smith and Nephew, Hull, United Kingdom) and protected by rabbit jackets. Long-acting Insulin-Zinc Suspension was selected for local injection. In study 1, Insulin was injected into the wound at different doses, and the concentrations of blood glucose and wound Insulin were measured to determine the proper dose and injection frequency. In study 2, wound healing days were compared between two groups ( n = 7 each) receiving local injection of either Insulin-Zinc or Zinc alone as control. Based on the results from study 1, a dose of 0.25 units of long-acting Insulin-Zinc Suspension was injected into the wound every other day in the Insulin group. Results After injection, 0.25 units of Insulin decreased blood glucose concentration (minimum 60 mg/dL) during the first 3 h, which then returned to the preinjection level (80 mg/dL). One injection maintained wound Insulin concentration above 50 μU/mL for more than 24 h. With local injection of 0.25 units Insulin-Zinc every other day, the wound healing time was 11.2 ± 2.3 d, which was faster ( P = 0.02) than 15.1 ± 4.1 d in the control group. Conclusion Local injection of long-acting Insulin-Zinc Suspension accelerated skin wound healing without major systemic side effects, demonstrating its potential usefulness in burn treatment.
Xiao-jun Zhang - One of the best experts on this subject based on the ideXlab platform.
-
106 Local Injection of Insulin‐Zinc Suspension Stimulates DNA Synthesis in Skin Donor Wound
Wound Repair and Regeneration, 2008Co-Authors: Xiao-jun Zhang, David L. Chinkes, Robert R. WolfeAbstract:We have previously reported that local injection of small doses of long-acting Insulin-Zinc Suspension maintained sufficiently high Insulin concentration in the wound fluid and accelerated the healing. The present experiment was to measure the rates of cell proliferation (reflected by DNA synthesis) and protein metabolism in the wound. These are the underlying metabolic processes responsible for the healing. Partial thickness skin donor wound was created on the back and indwelling catheters were placed in the carotid artery and jugular vein in adult rabbits under general anesthesia. The wound was covered with Aquaphor gauze, OpSite membrane, and surgical gauze. On day 7 after wounding, the wound was either injected with 0.2 units of Insulin-Zn, Zn alone, or no injection; stable isotopes were infused into the jugular vein catheter in conscious rabbits for measurement of DNA synthesis, protein synthesis and breakdown in the wound. The local Insulin-Zn injection raised wound Insulin concentration to 168 ± 39 μU/ml. In contrast, in the control and Zn groups wound Insulin concentrations were below the detectable level. The local injection of Insulin-Zn Suspension increased (p = 0.03) DNA synthesis in the wound with minor changes in blood glucose concentration which did not require exogenous glucose replacement. In the Zn group, whereas the rate of DNA synthesis tended to increase (p = 0.051 vs. control), the protein net balance (synthesis – breakdown) was lower (p
-
106 local injection of Insulin Zinc Suspension stimulates dna synthesis in skin donor wound
Wound Repair and Regeneration, 2008Co-Authors: Xiao-jun Zhang, David L. Chinkes, Robert R. WolfeAbstract:We have previously reported that local injection of small doses of long-acting Insulin-Zinc Suspension maintained sufficiently high Insulin concentration in the wound fluid and accelerated the healing. The present experiment was to measure the rates of cell proliferation (reflected by DNA synthesis) and protein metabolism in the wound. These are the underlying metabolic processes responsible for the healing. Partial thickness skin donor wound was created on the back and indwelling catheters were placed in the carotid artery and jugular vein in adult rabbits under general anesthesia. The wound was covered with Aquaphor gauze, OpSite membrane, and surgical gauze. On day 7 after wounding, the wound was either injected with 0.2 units of Insulin-Zn, Zn alone, or no injection; stable isotopes were infused into the jugular vein catheter in conscious rabbits for measurement of DNA synthesis, protein synthesis and breakdown in the wound. The local Insulin-Zn injection raised wound Insulin concentration to 168 ± 39 μU/ml. In contrast, in the control and Zn groups wound Insulin concentrations were below the detectable level. The local injection of Insulin-Zn Suspension increased (p = 0.03) DNA synthesis in the wound with minor changes in blood glucose concentration which did not require exogenous glucose replacement. In the Zn group, whereas the rate of DNA synthesis tended to increase (p = 0.051 vs. control), the protein net balance (synthesis – breakdown) was lower (p < 0.05) than those in the control and Insulin-Zn (Table 1). We conclude that local injection of a small dose (0.2 units Insulin) long-acting Insulin-Zn Suspension stimulated wound DNA synthesis without major systemic side effects thereby providing an effective and safe approach to accelerate wound healing. Although local Zn injection might also stimulate wound DNA synthesis, the benefit on the healing process was limited by decreased net protein deposition. Table 1. Wound DNA and protein metabolism. DNA synthesis Protein synthesis Protein net balance Values are means ± SD in %/d. * p < 0.05 vs. control; + p = 0.051 vs. control;#, p < 0.05 vs. control and Insulin-Zn by one-way ANOVA. Control (n = 7) 2.9 ± 0.9 20.5 ± 8.4 7.9 ± 6.0 Insulin-Zn (n = 7) 4.2 ± 0.9* 17.9 ± 8.2 9.4 ± 6.4 Zn (n = 7) 4.1 ± 0.9+ 13.0 ± 5.8 −0.2 ± 3.4#
-
Local Insulin-Zinc injection accelerates skin donor site wound healing.
Journal of Surgical Research, 2007Co-Authors: Xiao-jun Zhang, David L. Chinkes, Steven E. Wolf, Hal K. Hawkins, Robert R. WolfeAbstract:Background Systemically administered Insulin has been shown to accelerate wound healing. To minimize the hypoglycemic and hypokalemic effects of Insulin, we investigated a new route of Insulin administration by local injection into skin wounds. Materials and methods Partial thickness skin donor site wounds were created on the backs of adult rabbits with a dermatome set at 0.015 inch. The wounds were covered by Aquaphor gauze (Smith and Nephew, Largo, FL), and OpSite membrane (Smith and Nephew, Hull, United Kingdom) and protected by rabbit jackets. Long-acting Insulin-Zinc Suspension was selected for local injection. In study 1, Insulin was injected into the wound at different doses, and the concentrations of blood glucose and wound Insulin were measured to determine the proper dose and injection frequency. In study 2, wound healing days were compared between two groups ( n = 7 each) receiving local injection of either Insulin-Zinc or Zinc alone as control. Based on the results from study 1, a dose of 0.25 units of long-acting Insulin-Zinc Suspension was injected into the wound every other day in the Insulin group. Results After injection, 0.25 units of Insulin decreased blood glucose concentration (minimum 60 mg/dL) during the first 3 h, which then returned to the preinjection level (80 mg/dL). One injection maintained wound Insulin concentration above 50 μU/mL for more than 24 h. With local injection of 0.25 units Insulin-Zinc every other day, the wound healing time was 11.2 ± 2.3 d, which was faster ( P = 0.02) than 15.1 ± 4.1 d in the control group. Conclusion Local injection of long-acting Insulin-Zinc Suspension accelerated skin wound healing without major systemic side effects, demonstrating its potential usefulness in burn treatment.
David L. Chinkes - One of the best experts on this subject based on the ideXlab platform.
-
106 Local Injection of Insulin‐Zinc Suspension Stimulates DNA Synthesis in Skin Donor Wound
Wound Repair and Regeneration, 2008Co-Authors: Xiao-jun Zhang, David L. Chinkes, Robert R. WolfeAbstract:We have previously reported that local injection of small doses of long-acting Insulin-Zinc Suspension maintained sufficiently high Insulin concentration in the wound fluid and accelerated the healing. The present experiment was to measure the rates of cell proliferation (reflected by DNA synthesis) and protein metabolism in the wound. These are the underlying metabolic processes responsible for the healing. Partial thickness skin donor wound was created on the back and indwelling catheters were placed in the carotid artery and jugular vein in adult rabbits under general anesthesia. The wound was covered with Aquaphor gauze, OpSite membrane, and surgical gauze. On day 7 after wounding, the wound was either injected with 0.2 units of Insulin-Zn, Zn alone, or no injection; stable isotopes were infused into the jugular vein catheter in conscious rabbits for measurement of DNA synthesis, protein synthesis and breakdown in the wound. The local Insulin-Zn injection raised wound Insulin concentration to 168 ± 39 μU/ml. In contrast, in the control and Zn groups wound Insulin concentrations were below the detectable level. The local injection of Insulin-Zn Suspension increased (p = 0.03) DNA synthesis in the wound with minor changes in blood glucose concentration which did not require exogenous glucose replacement. In the Zn group, whereas the rate of DNA synthesis tended to increase (p = 0.051 vs. control), the protein net balance (synthesis – breakdown) was lower (p
-
106 local injection of Insulin Zinc Suspension stimulates dna synthesis in skin donor wound
Wound Repair and Regeneration, 2008Co-Authors: Xiao-jun Zhang, David L. Chinkes, Robert R. WolfeAbstract:We have previously reported that local injection of small doses of long-acting Insulin-Zinc Suspension maintained sufficiently high Insulin concentration in the wound fluid and accelerated the healing. The present experiment was to measure the rates of cell proliferation (reflected by DNA synthesis) and protein metabolism in the wound. These are the underlying metabolic processes responsible for the healing. Partial thickness skin donor wound was created on the back and indwelling catheters were placed in the carotid artery and jugular vein in adult rabbits under general anesthesia. The wound was covered with Aquaphor gauze, OpSite membrane, and surgical gauze. On day 7 after wounding, the wound was either injected with 0.2 units of Insulin-Zn, Zn alone, or no injection; stable isotopes were infused into the jugular vein catheter in conscious rabbits for measurement of DNA synthesis, protein synthesis and breakdown in the wound. The local Insulin-Zn injection raised wound Insulin concentration to 168 ± 39 μU/ml. In contrast, in the control and Zn groups wound Insulin concentrations were below the detectable level. The local injection of Insulin-Zn Suspension increased (p = 0.03) DNA synthesis in the wound with minor changes in blood glucose concentration which did not require exogenous glucose replacement. In the Zn group, whereas the rate of DNA synthesis tended to increase (p = 0.051 vs. control), the protein net balance (synthesis – breakdown) was lower (p < 0.05) than those in the control and Insulin-Zn (Table 1). We conclude that local injection of a small dose (0.2 units Insulin) long-acting Insulin-Zn Suspension stimulated wound DNA synthesis without major systemic side effects thereby providing an effective and safe approach to accelerate wound healing. Although local Zn injection might also stimulate wound DNA synthesis, the benefit on the healing process was limited by decreased net protein deposition. Table 1. Wound DNA and protein metabolism. DNA synthesis Protein synthesis Protein net balance Values are means ± SD in %/d. * p < 0.05 vs. control; + p = 0.051 vs. control;#, p < 0.05 vs. control and Insulin-Zn by one-way ANOVA. Control (n = 7) 2.9 ± 0.9 20.5 ± 8.4 7.9 ± 6.0 Insulin-Zn (n = 7) 4.2 ± 0.9* 17.9 ± 8.2 9.4 ± 6.4 Zn (n = 7) 4.1 ± 0.9+ 13.0 ± 5.8 −0.2 ± 3.4#
-
Local Insulin-Zinc injection accelerates skin donor site wound healing.
Journal of Surgical Research, 2007Co-Authors: Xiao-jun Zhang, David L. Chinkes, Steven E. Wolf, Hal K. Hawkins, Robert R. WolfeAbstract:Background Systemically administered Insulin has been shown to accelerate wound healing. To minimize the hypoglycemic and hypokalemic effects of Insulin, we investigated a new route of Insulin administration by local injection into skin wounds. Materials and methods Partial thickness skin donor site wounds were created on the backs of adult rabbits with a dermatome set at 0.015 inch. The wounds were covered by Aquaphor gauze (Smith and Nephew, Largo, FL), and OpSite membrane (Smith and Nephew, Hull, United Kingdom) and protected by rabbit jackets. Long-acting Insulin-Zinc Suspension was selected for local injection. In study 1, Insulin was injected into the wound at different doses, and the concentrations of blood glucose and wound Insulin were measured to determine the proper dose and injection frequency. In study 2, wound healing days were compared between two groups ( n = 7 each) receiving local injection of either Insulin-Zinc or Zinc alone as control. Based on the results from study 1, a dose of 0.25 units of long-acting Insulin-Zinc Suspension was injected into the wound every other day in the Insulin group. Results After injection, 0.25 units of Insulin decreased blood glucose concentration (minimum 60 mg/dL) during the first 3 h, which then returned to the preinjection level (80 mg/dL). One injection maintained wound Insulin concentration above 50 μU/mL for more than 24 h. With local injection of 0.25 units Insulin-Zinc every other day, the wound healing time was 11.2 ± 2.3 d, which was faster ( P = 0.02) than 15.1 ± 4.1 d in the control group. Conclusion Local injection of long-acting Insulin-Zinc Suspension accelerated skin wound healing without major systemic side effects, demonstrating its potential usefulness in burn treatment.
Font A. - One of the best experts on this subject based on the ideXlab platform.
-
Treatment of 46 cats with porcine lente Insulin - a prospective, multicentre study
Elsevier, 2008Co-Authors: Michiels L., Boari A., Bonfanti U., Mandigers P., Reusch C E, Petrie G, Thollot I G, Rosenberg D, Mooney C, Font A.Abstract:This prospective, multicentre, non-blinded, open study followed 46 cats with diabetes mellitus during treatment with porcine lente Insulin (also known as porcine Insulin Zinc Suspension, CanInsulin, Intervet) for 16+/-1 weeks (stabilization phase), with additional monitoring of some cats (n=23) for a variable period. At least three of the following were present at initial presentation: appropriate history of clinical signs consistent with diabetes mellitus, glucosuria, blood glucose greater than 15 mmol/l and fructosamine greater than 380 micromol/l. Insulin treatment was started at a dose rate of 0.25-0.5 IU/kg body weight twice daily, with a maximum starting dose of 2 IU/injection. Twenty-eight of the cats were classed as reaching clinical stability during the study, in 23 of these cats this was during the stabilization phase. Seven cats went into remission during the stabilization phase and one of the cats in week 56. Clinical signs of hypoglycaemia, significantly associated with a dose of 3 units or 0.5 IU/kg or more per cat (twice daily), were observed in nine of the 46 cats during the stabilization phase and concomitant biochemical hypoglycaemia was recorded in most cases. Biochemical hypoglycaemia, recorded in 6% of the blood glucose curves performed during the stabilization phase, was significantly associated with a dose rate of 0.75 IU/kg or more twice daily. This further highlights the need for cautious stepwise changes in Insulin dose. The protocol used in the present study is suitable for and easy to use in practice. This study confirmed the efficacy and safety of porcine lente Insulin (CanInsulin) in diabetic cats under field conditions
-
Treatment of 46 cats with porcine Insulin Zinc Suspension – a prospective study
'Elsevier BV', 2008Co-Authors: Michiels L., Boari A., Bewig K., Bonfanti U., Clercx Cécile, Font A., Goy Thollot, Lundorff A., Jensen P., Mandigers P.Abstract:peer reviewedaudience: researcher, professional, studentThis prospective, multicentre, non-blinded, open study followed 46 cats with diabetes mellitus during treatment with porcine lente Insulin (also known as porcine Insulin Zinc Suspension, CanInsulin, Intervet) for 16+/-1 weeks (stabilization phase), with additional monitoring of some cats (n=23) for a variable period. At least three of the following were present at initial presentation: appropriate history of clinical signs consistent with diabetes mellitus, glucosuria, blood glucose greater than 15 mmol/l and fructosamine greater than 380 micromol/l. Insulin treatment was started at a dose rate of 0.25-0.5 IU/kg body weight twice daily, with a maximum starting dose of 2 IU/injection. Twenty-eight of the cats were classed as reaching clinical stability during the study, in 23 of these cats this was during the stabilization phase. Seven cats went into remission during the stabilization phase and one of the cats in week 56. Clinical signs of hypoglycaemia, significantly associated with a dose of 3 units or 0.5 IU/kg or more per cat (twice daily), were observed in nine of the 46 cats during the stabilization phase and concomitant biochemical hypoglycaemia was recorded in most cases. Biochemical hypoglycaemia, recorded in 6% of the blood glucose curves performed during the stabilization phase, was significantly associated with a dose rate of 0.75 IU/kg or more twice daily. This further highlights the need for cautious stepwise changes in Insulin dose. The protocol used in the present study is suitable for and easy to use in practice. This study confirmed the efficacy and safety of porcine lente Insulin (CanInsulin) in diabetic cats under field conditions
-
Treatment of 46 cats with porcine Insulin Zinc Suspension – a prospective study
2008Co-Authors: Michiels L., Boari A., Bewig K., Bonfanti U., Clercx Cécile, Font A., Goy Thollot, Lundorff A., Jensen P., Mandigers P.Abstract:This prospective, multicentre, non-blinded, open study followed 46 cats with diabetes mellitus during treatment with porcine lente Insulin (also known as porcine Insulin Zinc Suspension, CanInsulin, Intervet) for 16+/-1 weeks (stabilization phase), with additional monitoring of some cats (n=23) for a variable period. At least three of the following were present at initial presentation: appropriate history of clinical signs consistent with diabetes mellitus, glucosuria, blood glucose greater than 15 mmol/l and fructosamine greater than 380 micromol/l. Insulin treatment was started at a dose rate of 0.25-0.5 IU/kg body weight twice daily, with a maximum starting dose of 2 IU/injection. Twenty-eight of the cats were classed as reaching clinical stability during the study, in 23 of these cats this was during the stabilization phase. Seven cats went into remission during the stabilization phase and one of the cats in week 56. Clinical signs of hypoglycaemia, significantly associated with a dose of 3 units or 0.5 IU/kg or more per cat (twice daily), were observed in nine of the 46 cats during the stabilization phase and concomitant biochemical hypoglycaemia was recorded in most cases. Biochemical hypoglycaemia, recorded in 6% of the blood glucose curves performed during the stabilization phase, was significantly associated with a dose rate of 0.75 IU/kg or more twice daily. This further highlights the need for cautious stepwise changes in Insulin dose. The protocol used in the present study is suitable for and easy to use in practice. This study confirmed the efficacy and safety of porcine lente Insulin (CanInsulin) in diabetic cats under field conditions.Peer reviewe
-
Treatment of 46 cats with porcine lente Insulin - a prospective, multicentre study
'Elsevier BV', 2008Co-Authors: Michiels L., Boari A., Bonfanti U., Mandigers P., Petrie G, Rosenberg D, Mooney C, Font A.Abstract:This prospective, multicentre, non-blinded, open study followed 46 cats with diabetes mellitus during treatment with porcine lente Insulin (also known as porcine Insulin Zinc Suspension, CanInsulin (R), Intervet) for 16 1 weeks (stabilization phase), with additional monitoring of some cats (n = 23) for a variable period. At least three of the following were present at initial presentation: appropriate history of clinical signs consistent with diabetes mellitus, glucosuria, blood glucose greater than 15 mmol/l and fructosamine greater than 380 mu mol/l. Insulin treatment was started at a dose rate of 0.25-0.5 IU/kg body weight twice daily, with a maximum starting dose of 2 IU/ injection. Twenty-eight of the cats were classed as reaching clinical stability during the study, in 23 of these cats this was during the stabilization phase. Seven cats went into remission during the stabilization phase and one of the cats in week 56. Clinical signs of hypoglycaemia, significantly associated with a dose of 3 units or 0.5 IU/kg or more per cat (twice daily), were observed in nine of the 46 cats during the stabilization phase and concomitant biochemical hypoglycaemia was recorded in most cases. Biochemical hypoglycaemia, recorded in 6% of the blood glucose curves performed during the stabilization phase, was significantly associated with a dose rate of 0.75 IU/kg or more twice daily. This further highlights the need for cautious stepwise changes in Insulin dose. The protocol used in the present study is suitable for and easy to use in practice. This study confirmed the efficacy and safety of porcine lente Insulin (CanInsulin) in diabetic cats under field conditions. (C) 2008 ESFM and AAFR Published by Elsevier Ltd. All rights reserved.[...
Mandigers P. - One of the best experts on this subject based on the ideXlab platform.
-
Treatment of 46 cats with porcine lente Insulin - a prospective, multicentre study
Elsevier, 2008Co-Authors: Michiels L., Boari A., Bonfanti U., Mandigers P., Reusch C E, Petrie G, Thollot I G, Rosenberg D, Mooney C, Font A.Abstract:This prospective, multicentre, non-blinded, open study followed 46 cats with diabetes mellitus during treatment with porcine lente Insulin (also known as porcine Insulin Zinc Suspension, CanInsulin, Intervet) for 16+/-1 weeks (stabilization phase), with additional monitoring of some cats (n=23) for a variable period. At least three of the following were present at initial presentation: appropriate history of clinical signs consistent with diabetes mellitus, glucosuria, blood glucose greater than 15 mmol/l and fructosamine greater than 380 micromol/l. Insulin treatment was started at a dose rate of 0.25-0.5 IU/kg body weight twice daily, with a maximum starting dose of 2 IU/injection. Twenty-eight of the cats were classed as reaching clinical stability during the study, in 23 of these cats this was during the stabilization phase. Seven cats went into remission during the stabilization phase and one of the cats in week 56. Clinical signs of hypoglycaemia, significantly associated with a dose of 3 units or 0.5 IU/kg or more per cat (twice daily), were observed in nine of the 46 cats during the stabilization phase and concomitant biochemical hypoglycaemia was recorded in most cases. Biochemical hypoglycaemia, recorded in 6% of the blood glucose curves performed during the stabilization phase, was significantly associated with a dose rate of 0.75 IU/kg or more twice daily. This further highlights the need for cautious stepwise changes in Insulin dose. The protocol used in the present study is suitable for and easy to use in practice. This study confirmed the efficacy and safety of porcine lente Insulin (CanInsulin) in diabetic cats under field conditions
-
Treatment of 46 cats with porcine Insulin Zinc Suspension – a prospective study
'Elsevier BV', 2008Co-Authors: Michiels L., Boari A., Bewig K., Bonfanti U., Clercx Cécile, Font A., Goy Thollot, Lundorff A., Jensen P., Mandigers P.Abstract:peer reviewedaudience: researcher, professional, studentThis prospective, multicentre, non-blinded, open study followed 46 cats with diabetes mellitus during treatment with porcine lente Insulin (also known as porcine Insulin Zinc Suspension, CanInsulin, Intervet) for 16+/-1 weeks (stabilization phase), with additional monitoring of some cats (n=23) for a variable period. At least three of the following were present at initial presentation: appropriate history of clinical signs consistent with diabetes mellitus, glucosuria, blood glucose greater than 15 mmol/l and fructosamine greater than 380 micromol/l. Insulin treatment was started at a dose rate of 0.25-0.5 IU/kg body weight twice daily, with a maximum starting dose of 2 IU/injection. Twenty-eight of the cats were classed as reaching clinical stability during the study, in 23 of these cats this was during the stabilization phase. Seven cats went into remission during the stabilization phase and one of the cats in week 56. Clinical signs of hypoglycaemia, significantly associated with a dose of 3 units or 0.5 IU/kg or more per cat (twice daily), were observed in nine of the 46 cats during the stabilization phase and concomitant biochemical hypoglycaemia was recorded in most cases. Biochemical hypoglycaemia, recorded in 6% of the blood glucose curves performed during the stabilization phase, was significantly associated with a dose rate of 0.75 IU/kg or more twice daily. This further highlights the need for cautious stepwise changes in Insulin dose. The protocol used in the present study is suitable for and easy to use in practice. This study confirmed the efficacy and safety of porcine lente Insulin (CanInsulin) in diabetic cats under field conditions
-
Treatment of 46 cats with porcine Insulin Zinc Suspension – a prospective study
2008Co-Authors: Michiels L., Boari A., Bewig K., Bonfanti U., Clercx Cécile, Font A., Goy Thollot, Lundorff A., Jensen P., Mandigers P.Abstract:This prospective, multicentre, non-blinded, open study followed 46 cats with diabetes mellitus during treatment with porcine lente Insulin (also known as porcine Insulin Zinc Suspension, CanInsulin, Intervet) for 16+/-1 weeks (stabilization phase), with additional monitoring of some cats (n=23) for a variable period. At least three of the following were present at initial presentation: appropriate history of clinical signs consistent with diabetes mellitus, glucosuria, blood glucose greater than 15 mmol/l and fructosamine greater than 380 micromol/l. Insulin treatment was started at a dose rate of 0.25-0.5 IU/kg body weight twice daily, with a maximum starting dose of 2 IU/injection. Twenty-eight of the cats were classed as reaching clinical stability during the study, in 23 of these cats this was during the stabilization phase. Seven cats went into remission during the stabilization phase and one of the cats in week 56. Clinical signs of hypoglycaemia, significantly associated with a dose of 3 units or 0.5 IU/kg or more per cat (twice daily), were observed in nine of the 46 cats during the stabilization phase and concomitant biochemical hypoglycaemia was recorded in most cases. Biochemical hypoglycaemia, recorded in 6% of the blood glucose curves performed during the stabilization phase, was significantly associated with a dose rate of 0.75 IU/kg or more twice daily. This further highlights the need for cautious stepwise changes in Insulin dose. The protocol used in the present study is suitable for and easy to use in practice. This study confirmed the efficacy and safety of porcine lente Insulin (CanInsulin) in diabetic cats under field conditions.Peer reviewe
-
Treatment of 46 cats with porcine lente Insulin - a prospective, multicentre study
'Elsevier BV', 2008Co-Authors: Michiels L., Boari A., Bonfanti U., Mandigers P., Petrie G, Rosenberg D, Mooney C, Font A.Abstract:This prospective, multicentre, non-blinded, open study followed 46 cats with diabetes mellitus during treatment with porcine lente Insulin (also known as porcine Insulin Zinc Suspension, CanInsulin (R), Intervet) for 16 1 weeks (stabilization phase), with additional monitoring of some cats (n = 23) for a variable period. At least three of the following were present at initial presentation: appropriate history of clinical signs consistent with diabetes mellitus, glucosuria, blood glucose greater than 15 mmol/l and fructosamine greater than 380 mu mol/l. Insulin treatment was started at a dose rate of 0.25-0.5 IU/kg body weight twice daily, with a maximum starting dose of 2 IU/ injection. Twenty-eight of the cats were classed as reaching clinical stability during the study, in 23 of these cats this was during the stabilization phase. Seven cats went into remission during the stabilization phase and one of the cats in week 56. Clinical signs of hypoglycaemia, significantly associated with a dose of 3 units or 0.5 IU/kg or more per cat (twice daily), were observed in nine of the 46 cats during the stabilization phase and concomitant biochemical hypoglycaemia was recorded in most cases. Biochemical hypoglycaemia, recorded in 6% of the blood glucose curves performed during the stabilization phase, was significantly associated with a dose rate of 0.75 IU/kg or more twice daily. This further highlights the need for cautious stepwise changes in Insulin dose. The protocol used in the present study is suitable for and easy to use in practice. This study confirmed the efficacy and safety of porcine lente Insulin (CanInsulin) in diabetic cats under field conditions. (C) 2008 ESFM and AAFR Published by Elsevier Ltd. All rights reserved.[...